A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer KisMET-01

Go Back to All Clinical Trials

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer KisMET-01

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Nsclc
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy) or metastatic NSCLC and have received available standard of care therapy
2. Cardiac left ventricular ejection fraction (LVEF) greater than or equal to 50%

You may not be eligible for this study if the following are true:

1. Radiation to the lung within 2 months prior to screening
2. Major surgery within 28 days of first dose of study drug administration
3. Previously received cMET targeted antibody or ADC, bicycle, or small peptide therapies targeting cMET

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies